Список литературы к Главе 12

80. Hillmen P. et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open­label phase 3 trial // Lancet. 2015. Vol. 385, N 9980. P. 1873–1883.

81. Dartigeas C. et al. Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose­dense rituximab in elderly patients with chronic lymphocytic leukemia // Leuk. Lymphoma. 2016. Vol. 57, N 2. P. 328–334.

82. Michallet A.­S. et al. Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open­label MABLE study // Haematologica. 2018. Vol. 103, N 4. P. 698.

83. Mato A.R. et al. Reduced­dose fludarabine, cyclophosphamide, and rituximab (FCR­Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia // Am. J. Hematol. 2015. Vol. 90, N 6. P. 487–492.

84. Greil R. et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first­line or second­line rituximab­containing chemoimmunotherapy: final results of the AGMT CLL­8a Mabtenance randomised trial // Lancet Haematol. 2016. Vol. 3, N 7. P. e317–e329.

85. van Oers M. et al. Ofatumumab maintenance prolongs progression­free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study // Blood Cancer J. 2019. Vol. 9, N 12. P. 98.

86. Sher T. et al. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high­risk cytogenetics // Leuk. Lymphoma. 2010. Vol. 51, N 1. P. 85–88.

87. Chanan­Khan A. et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study // J. Clin. Oncol. 2006. Vol. 24, N 34. P. 5343–5349.

88. Ferrajoli A. et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia // Blood. 2008. Vol. 111, N 11. P. 5291–5297.

89. Strati P. et al. Lenalidomide induces long­lasting responses in elderly patients with chronic lymphocytic leukemia // Blood. 2013. Vol. 122, N 5. P. 734–737.

90. Fink A.M. et al. Lenalidomide maintenance after first­line therapy for high­risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double­blind, phase 3 study // Lancet Haematol. 2017. Vol. 4, N 10. P. e475–e486.

91. Chanan­Khan A.A. et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double­blind, placebo­controlled, phase 3 trial // Lancet Haematol. 2017. Vol. 4, N 11. P. e534–e543.

92. Moutouh­de Parseval L.A. et al. Tumor lysis syndrome/tumor flare reaction in lenalidomide­treated chronic lymphocytic leukemia // J. Clin. Oncol. 2007. Vol. 25, N 31. P. 5047.

93. Zenz T. et al. Risk categories and refractory CLL in the era of chemoimmunotherapy // Blood. 2012. Vol. 119, N 18. P. 4101–4107.

94. Ahn I.E. et al. Early progression of disease as a predictor of survival in chronic lymphocytic leukemia // Blood Adv. 2017. Vol. 1, N 25. P. 2433–2443.

95. Eichhorst B. et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow­up // Ann. Oncol. 2015. Vol. 26, suppl. 5. P. v78–v84.

96. Cramer P. et al. Outcome of advanced chronic lymphocytic leukemia following different first­line and relapse therapies: a meta­analysis of five prospective trials by the German CLL Study Group (GCLLSG) // Haematologica. 2015. Vol. 100, N 11. P. 1451–1459.

97. Fornecker L.M. et al. Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: the French intergroup experience // Am. J. Hematol. 2015. Vol. 90, N 6. P. 511–514.

98. Robak T. et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression­free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia // J. Clin. Oncol. 2010. Vol. 28, N 10. P. 1756–1765.

99. Robak T. et al. Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial // Leuk. Lymphoma. 2017. Vol. 58, N 5. P. 1084–1093.

100. Awan F.T. et al. A randomized, open­label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia // Br. J. Haematol. 2014. Vol. 167, N 4. P. 466–477.

101. Elter T. et al. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial // Lancet Oncol. 2011. Vol. 12, N 13. P. 1204–1213.

102. Faderl S. et al. Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM­R) in frontline CLL <70 years // Leuk. Res. 2010. Vol. 34, N 3. P. 284-288.

103. Badoux X.C. et al. Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia // Blood. 2011. Vol. 118, N 8. P. 2085–2093.

104. Dlouhy I. et al. Retreatment with purine analogs in patients with chronic lymphocytic leukemia // Leuk. Res. 2012. Vol. 36, N 12. P. 1521–1525.

105. Fischer K. et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group // J. Clin. Oncol. 2011. Vol. 29, N 26. P. 3559–3566.

106. Mato A.R. et al. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience // Blood. 2016. Vol. 128, N 18. P. 2199–2205.

107. Cartron G. et al. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study // Blood. 2014. Vol. 124, N 14. P. 2196–2202.

108. Keating M.J. et al. Therapeutic role of alemtuzumab (Campath­1H) in patients who have failed fludarabine: results of a large international study // Blood. 2002. Vol. 99, N 10. P. 3554–3561.

109. Elter T. et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B­cell chronic lymphocytic leukemia: results of a phase II trial // J. Clin. Oncol. 2005. Vol. 23, N 28. P. 7024–7031.

110. Castro J.E. et al. Rituximab in combination with high­dose methylprednisolone for the treatment of fludarabine refractory high­risk chronic lymphocytic leukemia // Leukemia. 2008. Vol. 22, N 11. P. 2048–2053.

111. Bowen D.A. et al. Methylprednisolone­rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features // Leuk. Lymphoma. 2007. Vol. 48, N 12. P. 2412–2417.